Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AcNK-Sup003 in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
NCT07345741Not yet recruiting
- Start
- Dec 2025
- Primary completion
- Dec 2029
- Modality
- Antibody Conjugates, Cell Therapies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Open-label, single-arm trial of AcNK-Sup003 in B-cell non-Hodgkin lymphoma. Primary endpoint: Overall survival at 24 months. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
AcNK-Sup003
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT07345741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07345741.